SEC Info - Omega Healthcare Investors Inc. - ‘10-K’ for 12/31/22

Omega Healthcare Investors Inc. – ‘10-K’ for 12/31/22 – ‘EX-31.2’

On: Tuesday, 2/14/23, at 10:15am ET · For: 12/31/22 · Accession #: 888491-23-6 · File #: 1-11316

Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 6.18M 2: EX-4.10 Instrument Defining the Rights of Security Holders HTML 84K 3: EX-10.10 Material Contract HTML 80K 4: EX-21.1 Subsidiaries List HTML 740K 5: EX-22.1 Published Report re: Matters Submitted to a Vote HTML 41K of Security Holders 6: EX-23.1 Consent of Expert or Counsel HTML 41K 7: EX-31.1 Certification -- §302 - SOA'02 HTML 44K 8: EX-31.2 Certification -- §302 - SOA'02 HTML 44K 9: EX-32.1 Certification -- §906 - SOA'02 HTML 41K 10: EX-32.2 Certification -- §906 - SOA'02 HTML 41K 16: R1 Document and Entity Information HTML 106K 17: R2 Consolidated Balance Sheets HTML 159K 18: R3 Consolidated Balance Sheets (Parentheticals) HTML 57K 19: R4 Consolidated Statements of Operations HTML 137K 20: R5 Consolidated Statements of Comprehensive Income HTML 73K 21: R6 Consolidated Statements of Equity HTML 116K 22: R7 Consolidated Statements of Equity (Parentheticals) HTML 42K 23: R8 Consolidated Statements of Cash Flows HTML 154K 24: R9 Organization HTML 44K 25: R10 Summary of Significant Accounting Policies HTML 145K 26: R11 Real Estate Asset Acquisitions and Developments HTML 143K 27: R12 Assets Held for Sale, Dispositions and Impairments HTML 58K 28: R13 Contractual Receivables and Other Receivables and HTML 115K Lease Inducements 29: R14 Leases HTML 98K 30: R15 Real Estate Loans Receivable HTML 131K 31: R16 Non-Real Estate Loans Receivable HTML 94K 32: R17 Allowance for Credit Losses HTML 446K 33: R18 Variable Interest Entities HTML 117K 34: R19 Investment in Joint Ventures HTML 120K 35: R20 Goodwill and Other Intangibles HTML 76K 36: R21 Concentration of Risk HTML 43K 37: R22 Borrowing Activities and Arrangements HTML 177K 38: R23 Derivatives and Hedging HTML 61K 39: R24 Financial Instruments HTML 123K 40: R25 Taxes HTML 81K 41: R26 Stockholders Equity HTML 157K 42: R27 Stock-Based Compensation HTML 140K 43: R28 Commitments and Contingencies HTML 70K 44: R29 Supplemental Disclosure to Consolidated Statements HTML 101K of Cash Flows 45: R30 Earnings Per Share HTML 78K 46: R31 Schedule Iii - Real Estate and Accumulated HTML 465K Depreciation 47: R32 Schedule Iv - Mortgage Loans on Real Estate HTML 287K 48: R33 Summary of Significant Accounting Policies HTML 209K (Policies) 49: R34 Summary of Significant Accounting Policies HTML 68K (Tables) 50: R35 Real Estate Asset Acquisitions and Developments HTML 136K (Tables) 51: R36 Assets Held for Sale, Dispositions and Impairments HTML 48K (Tables) 52: R37 Contractual Receivables and Other Receivables and HTML 58K Lease Inducements (Tables) 53: R38 Leases (Tables) HTML 103K 54: R39 Real Estate Loans Receivable (Tables) HTML 97K 55: R40 Non-Real Estate Loans Receivable (Tables) HTML 73K 56: R41 Allowance for Credit Losses (Tables) HTML 447K 57: R42 Variable Interest Entities (Tables) HTML 119K 58: R43 Investment in Joint Ventures (Tables) HTML 117K 59: R44 Goodwill and Other Intangibles (Tables) HTML 79K 60: R45 Borrowing Activities and Arrangements (Tables) HTML 161K 61: R46 Derivatives and Hedging (Tables) HTML 53K 62: R47 Financial Instruments (Tables) HTML 117K 63: R48 Taxes (Tables) HTML 77K 64: R49 Stockholders Equity (Tables) HTML 152K 65: R50 Stock-Based Compensation (Tables) HTML 130K 66: R51 Commitments and Contingencies (Tables) HTML 53K 67: R52 Supplemental Disclosure to Consolidated Statements HTML 100K of Cash Flows (Tables) 68: R53 Earnings Per Share (Tables) HTML 77K 69: R54 Organization and Basis of Presentation (Details) HTML 44K 70: R55 Summary of Significant Accounting Policies HTML 212K (Narrative) (Detail) 71: R56 Summary of Significant Accounting Policies HTML 79K (Investment reclassification) (Detail) 72: R57 Real Estate Asset Acquisitions and Developments HTML 99K (Narrative) (Details) 73: R58 Real Estate Asset Acquisitions and Developments HTML 186K (Schedule of Significant Acquisitions) (Detail) 74: R59 Assets Held for Sale, Dispositions and Impairments HTML 189K (Narrative) (Details) 75: R60 Assets Held for Sale, Dispositions and Impairments HTML 43K (Schedule of Properties Held-for-Sale) (Details) 76: R61 Contractual Receivables and Other Receivables and HTML 705K Lease Inducements (Narrative) (Details) 77: R62 Contractual Receivables and Other Receivables and HTML 50K Lease Inducements (Schedule of Net Accounts Receivable) (Detail) 78: R63 Leases (Narrative) (Detail) HTML 77K 79: R64 Leases (Schedule of operating lease income) HTML 46K (Details) 80: R65 Leases (Schedule of estimated contractual rents HTML 54K due under operating leases) (Details) 81: R66 Leases - Balance sheet information (Details) HTML 47K 82: R67 Leases (Schedule of Components of Investment in HTML 58K Direct Financing Leases) (Detail) 83: R68 Real Estate Loans Receivable (Narrative) (Detail) HTML 63K 84: R69 Real Estate Loans Receivable (Schedule of HTML 109K Receivables) (Detail) 85: R70 Real Estate Loans Receivable (Summary of HTML 49K investments income) (Details) 86: R71 Real Estate Loans Receivable (Notes Due 2030 HTML 221K Narrative) (Detail) 87: R72 Real Estate Loans Receivable (Notes Due 2031 HTML 134K Narrative) (Detail) 88: R73 Real Estate Loans Receivable (Other Mortgage Notes HTML 49K Outstanding) (Detail) 89: R74 Real Estate Loans Receivable (Other Mortgage Notes HTML 85K Due 2032) (Detail) 90: R75 Real Estate Loans Receivable (Mortgage Notes Due HTML 65K 2025) (Detail) 91: R76 Real Estate Loans Receivable (Other Real Estate HTML 76K Loans Due 2030) (Detail) 92: R77 Real Estate Loans Receivable (Other Real Estate HTML 70K Loans Due 2024 interest of 13.17 percent) (Detail) 93: R78 Real Estate Loans Receivable (Other Real Estate HTML 56K Loans Due 2022-2025) (Detail) 94: R79 Real Estate Loans Receivable (Other Real Estate HTML 57K Loans Due 2024 Interest of 12 percent) (Detail) 95: R80 Real Estate Loans Receivable (Other Real Estate HTML 47K Loans Other) (Detail) 96: R81 Non-Real Estate Loans Receivable (Narrative) HTML 48K (Details) 97: R82 Non-Real Estate Loans Receivable (Schedule of HTML 107K receivables) (Details) 98: R83 Non-Real Estate Loans Receivable (Notes due HTML 116K 2024-2025) (Details) 99: R84 Non-Real Estate Loans Receivable (Notes due HTML 79K 2022-2028) (Details) 100: R85 Non-Real Estate Loans Receivable (Notes due 2036) HTML 94K (Details) 101: R86 Non-Real Estate Loans Receivable (Note due 2027) HTML 52K (Details) 102: R87 Non-Real Estate Loans Receivable (Note due 2024) HTML 57K (Details) 103: R88 Non-Real Estate Loans Receivable (Other Notes) HTML 163K (Details) 104: R89 Allowance for Credit Losses (Narrative) (Detail) HTML 56K 105: R90 Allowance for Credit Losses (Schedule of expected HTML 264K credit loss per segment) (Detail) 106: R91 Allowance for Credit Losses (Schedule by segment HTML 131K balance by vintage and credit quality indicator) (Detail) 107: R92 Variable Interest Entities (Schedule of variable HTML 164K interest entities) (Detail) 108: R93 Investment in Joint Ventures (Narrative) (Details) HTML 48K 109: R94 Investment in Joint Ventures (Schedule of equity HTML 163K method investments) (Details) 110: R95 Goodwill and Other Intangibles (Narrative) HTML 56K (Details) 111: R96 Goodwill and Other Intangibles (Schedule of HTML 57K Reconciliation of Goodwill) (Detail) 112: R97 Goodwill and Other Intangibles (Schedule of HTML 53K Intangibles) (Detail) 113: R98 Concentration of Risk (Narrative) (Detail) HTML 103K 114: R99 Borrowing Arrangements (Schedule of Borrowings) HTML 285K (Details) 115: R100 Borrowing Arrangements (HUD Mortgage) (Details) HTML 83K 116: R101 Borrowing Arrangements (Revolving Credit Facility) HTML 64K (Details) 117: R102 Borrowing Arrangements (OP Term Loan) (Details) HTML 61K 118: R103 Borrowing Arrangements (Omega Credit Facilities, HTML 140K OP Term Loan, Amended 2015 Term Loan Facilities and General) (Detail) 119: R104 Borrowing Arrangements (Subordinated Debt) HTML 57K (Narrative) (Detail) 120: R105 Borrowing Arrangements (Schedule of principal HTML 58K payments, excluding the premium or discount and the aggregate due thereafter) (Detail) 121: R106 Derivatives and Hedging (Narrative) (Details) HTML 137K 122: R107 Derivatives and Hedging (Location and the fair HTML 49K value of derivative instruments designated as hedges) (Details) 123: R108 Financial Instruments (Schedule of Financial HTML 117K Instruments) (Details) 124: R109 Taxes (Narrative) (Detail) HTML 55K 125: R110 Taxes (Schedule of components of income tax HTML 58K expense) (Details) 126: R111 Taxes (Schedule of deferred tax assets and HTML 54K liabilities) (Detail) 127: R112 Stockholders Equity (Common Stock Repurchase) HTML 52K (Narrative) (Detail) 128: R113 Stockholders Equity (Schedule of Common Stock HTML 46K Dividends) (Details) 129: R114 Stockholders Equity (Schedule of dividend HTML 43K reinvestment and common stock purchase plan) (Detail) 130: R115 Stockholders Equity (At The Market Program HTML 59K Schedule and Narrative) (Detail) 131: R116 Stockholders Equity (Per Share Distributions) HTML 47K (Detail) 132: R117 Stockholders Equity (Schedule of Accumulated Other HTML 103K Comprehensive Income (Loss)) (Details) 133: R118 Stock-Based Compensation (Narrative) (Detail) HTML 81K 134: R119 Stock-Based Compensation (Schedule of assumptions HTML 50K used for estimating fair value of stock awards using Monte-Carlo model) (Detail) 135: R120 Stock-Based Compensation (Schedule of activity in HTML 80K restricted stock and RSUs) (Detail) 136: R121 Commitments and Contingencies (Narrative) HTML 63K (Details) 137: R122 Commitments and Contingencies (Schedule of HTML 51K remaining commitments) (Detail) 138: R123 Supplemental Disclosure to Consolidated Statements HTML 80K of Cash Flows (Detail) 139: R124 Earnings Per Share (Schedule of Computation of HTML 88K Basic and Diluted Earnings per Share) (Detail) 140: R125 Schedule Iii - Real Estate and Accumulated HTML 424K Depreciation (Detail) 141: R126 Schedule Iii - Real Estate and Accumulated HTML 60K Depreciation (Narrative) (Detail) 142: R127 Schedule Iii - Real Estate and Accumulated HTML 51K Depreciation (Narrative 1) (Detail) 143: R128 Schedule Iv - Mortgage Loans on Real Estate HTML 182K (Detail) 144: R129 Schedule Iv - Mortgage Loans on Real Estate HTML 55K (Narrative 1) (Detail) 145: R130 Schedule Iv - Mortgage Loans on Real Estate HTML 43K (Narrative 2) (Detail) 148: XML IDEA XML File -- Filing Summary XML 297K 146: XML XBRL Instance -- ohi-20221231x10k_htm XML 8.99M 147: EXCEL IDEA Workbook of Financial Reports XLSX 536K 12: EX-101.CAL XBRL Calculations -- ohi-20221231_cal XML 325K 13: EX-101.DEF XBRL Definitions -- ohi-20221231_def XML 2.42M 14: EX-101.LAB XBRL Labels -- ohi-20221231_lab XML 3.04M 15: EX-101.PRE XBRL Presentations -- ohi-20221231_pre XML 3.15M 11: EX-101.SCH XBRL Schema -- ohi-20221231 XSD 551K 149: JSON XBRL Instance as JSON Data -- MetaLinks 846± 1.41M 150: ZIP XBRL Zipped Folder -- 0000888491-23-000006-xbrl Zip 1.14M

Exhibit 31.2

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER

Certifications

I, Robert O. Stephenson, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Omega Healthcare Investors, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 14, 2023

	/S/ *ROBERT O. STEPHENSON*
	Robert O. Stephenson
	Chief Financial Officer

This ‘10-K’ Filing

Date

Other Filings

Filed on:

2/14/23

For Period end:

12/31/22

List all Filings

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/24 Omega Healthcare Investors Inc. 424B5 2:614K Toppan Merrill/FA 3/14/24 Omega Healthcare Investors Inc. 424B2 2:507K Toppan Merrill/FA 2/12/24 Omega Healthcare Investors Inc. 10-K 12/31/23 156:32M 11/03/23 Omega Healthcare Investors Inc. 10-Q 9/30/23 115:18M 8/03/23 Omega Healthcare Investors Inc. 10-Q 6/30/23 116:17M 6/06/23 Omega Healthcare Investors Inc. S-8 6/06/23 4:88K Toppan Merrill/FA 5/03/23 Omega Healthcare Investors Inc. 10-Q 3/31/23 105:14M

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/21/22 Omega Healthcare Investors Inc. 8-K:5,9 10/21/22 11:426K Toppan Merrill/FA 2/17/22 Omega Healthcare Investors Inc. 10-K 12/31/21 155:28M 5/20/21 Omega Healthcare Investors Inc. 8-K:8,9 5/20/21 14:1M Toppan Merrill/FA 5/04/21 Omega Healthcare Investors Inc. 8-K:1,2,9 4/30/21 12:2.8M Toppan Merrill/FA 3/10/21 Omega Healthcare Investors Inc. 8-K:1,2,9 3/10/21 14:1M Toppan Merrill/FA 11/03/20 Omega Healthcare Investors Inc. 10-Q 9/30/20 113:19M 10/09/20 Omega Healthcare Investors Inc. 8-K:1,2,9 10/07/20 16:1.1M Toppan Merrill/FA 2/28/20 Omega Healthcare Investors Inc. 10-K 12/31/19 159:33M 12/20/19 Omega Healthcare Investors Inc. 8-K:5,9 12/16/19 13:736K Toppan Merrill/FA 11/08/19 Omega Healthcare Investors Inc. 10-Q 9/30/19 109:16M 9/20/19 Omega Healthcare Investors Inc. 8-K:1,2,9 9/17/19 16:1.1M Toppan Merrill/FA 2/26/19 Omega Healthcare Investors Inc. 10-K 12/31/18 157:34M 8/08/18 Omega Healthcare Investors Inc. 10-Q 6/30/18 98:11M Toppan Merrill/FA 6/11/18 Omega Healthcare Investors Inc. 8-K:5,9 6/11/18 2:255K 2/23/18 Omega Healthcare Investors Inc. 10-K 12/31/17 152:17M Toppan Merrill/FA 8/09/17 Omega Healthcare Investors Inc. 10-Q 6/30/17 108:9.1M Toppan Vite NY Inc./FA 5/05/17 Omega Healthcare Investors Inc. 10-Q 3/31/17 100:8.7M Toppan Vite NY Inc./FA 4/04/17 Omega Healthcare Investors Inc. 8-K:1,2,9 4/04/17 15:2M Toppan Vite NY Inc./FA 2/24/17 Omega Healthcare Investors Inc. 10-K 12/31/16 141:19M Toppan Vite NY Inc./FA 11/08/16 Omega Healthcare Investors Inc. 10-Q 9/30/16 103:10M Toppan Vite NY Inc./FA 8/05/16 Omega Healthcare Investors Inc. 10-Q 6/30/16 103:9.7M Toppan Vite NY Inc./FA 7/12/16 Omega Healthcare Investors Inc. 8-K:1,2,9 7/12/16 15:2.1M Toppan Vite NY Inc./FA 5/06/16 Omega Healthcare Investors Inc. 10-Q 3/31/16 97:8.4M Toppan Vite NY Inc./FA 2/29/16 Omega Healthcare Investors Inc. 10-K 12/31/15 134:16M Toppan Vite NY Inc./FA 11/12/15 OHI Asset (IN) Monticello, LLC S-4 24:4.4M Toppan Vite NY Inc./FA 11/12/15 Seguin Texas Property, L.L.C. S-4/A 11/10/15 6:1.9M Toppan Vite NY Inc./FA 11/06/15 Omega Healthcare Investors Inc. 10-Q 9/30/15 101:10M Toppan Vite NY Inc./FA 10/06/15 Yuba Aviv, L.L.C. S-4 38:5.9M Toppan Vite NY Inc./FA 9/29/15 Omega Healthcare Investors Inc. 8-K:1,2,8,9 9/23/15 3:907K Toppan Vite NY Inc./FA 9/03/15 Omega Healthcare Investors Inc. S-3ASR 9/03/15 7:534K Toppan Vite NY Inc./FA 5/08/15 Omega Healthcare Investors Inc. 10-Q 3/31/15 91:13M Toppan Vite NY Inc./FA 4/16/15 Tulare County Property, L.L.C. S-4 78:7.6M Toppan Vite NY Inc./FA 4/03/15 Omega Healthcare Investors Inc. 8-K:1,2,5,8 3/31/15 18:8.3M Toppan Vite NY Inc./FA 3/24/15 Omega Healthcare Investors Inc. 8-K:1,2,9 3/18/15 3:888K Toppan Vite NY Inc./FA 2/27/15 Omega Healthcare Investors Inc. 10-K 12/31/14 132:27M Toppan Vite NY Inc./FA 9/11/14 Omega Healthcare Investors Inc. 8-K:1,2,9 9/11/14 3:854K Toppan Vite NY Inc./FA 8/06/14 Omega Healthcare Investors Inc. 10-Q 6/30/14 81:15M Toppan Vite NY Inc./FA 3/11/14 Omega Healthcare Investors Inc. 8-K:1,2,9 3/11/14 3:851K Toppan Vite NY Inc./FA 8/05/13 Omega Healthcare Investors Inc. 10-Q 6/30/13 115:16M Toppan Vite NY Inc./FA 11/07/12 Omega Healthcare Investors Inc. 10-Q 9/30/12 65:13M Toppan Vite NY Inc./FA

Omega Healthcare Investors Inc. – ‘10-K’ for 12/31/22 – ‘EX-31.2’

On: Tuesday, 2/14/23, at 10:15am ET · For: 12/31/22 · Accession #: 888491-23-6 · File #: 1-11316

Previous ‘10-K’: ‘10-K’ on 2/17/22 for 12/31/21 · Next & Latest: ‘10-K’ on 2/12/24 for 12/31/23 · 47 References:

Annual Report — Form 10-K

Filing Table of Contents

‘EX-31.2’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

7 Subsequent Filings that Reference this Filing

40 Previous Filings that this Filing References

Omega Healthcare Investors Inc. – ‘10-K’ for 12/31/22 – ‘EX-31.2’

On: Tuesday, 2/14/23, at 10:15am ET · For: 12/31/22 · Accession #: 888491-23-6 · File #: 1-11316

Annual Report — Form 10-KFiling Table of Contents

‘EX-31.2’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

7 Subsequent Filings that Reference this Filing

40 Previous Filings that this Filing References

Annual Report — Form 10-K

Filing Table of Contents